Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective
Austin, Texas, United States, February 5th, 2026, FinanceWire LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell […]








